The ubiquitin-proteasome system (UPS) is believed to degrade the major contractile skeletal muscle proteins and plays a major role in muscle wasting. Different and multiple events in the ubiquitination, deubiquitination and proteolytic machineries are responsible for the activation of the system and subsequent muscle wasting. However, other proteolytic enzymes act upstream (possibly m-calpain, cathepsin L, and/or caspase 3) and downstream (tripeptidyl-peptidase II and aminopeptidases) of the UPS, for the complete breakdown of the myofibrillar proteins into free amino acids. Recent studies have identified a few critical proteins that seem necessary for muscle wasting {i.e. the MAFbx (muscle atrophy F-box protein, also called atrogin-1) and MuRF-1 [muscle-specific RING (really interesting new gene) finger 1] ubiquitin-protein ligases}. The characterization of their signalling pathways is leading to new pharmacological approaches that can be useful to block or partially prevent muscle wasting in human patients.
Introduction
Skeletal muscle is the major protein reservoir in the body. This tissue exhibits very high plasticity and muscle proteins can be mobilized into free amino acids under disuse conditions (i.e. immobilization, denervation etc.), in starvation and in numerous pathological states (cancer cachexia, AIDS, sepsis, renal failure, diabetes, burn injury, trauma etc.) [1, 2] . In the latter instances, both depressed protein synthesis and enhanced proteolysis in skeletal muscle provide the organism with free amino acids. These amino acids are used for providing energy (by direct oxidation and neoglucogenesis), as precursors of acute-phase protein synthesis in the liver, and to maintain protein synthesis in vital organs (e.g. heart, brain, lungs) ( Figure 1 ). 
Whether muscle atrophy results mainly from either depressed protein synthesis or enhanced proteolysis in catabolic states is still a matter of debate. However, the increased proteolysis contributes greatly to muscle wasting; various treatments that only block muscle proteolysis, without any detectable effect on protein synthesis, result in an improvement in muscle mass (see [3] for an example). Furthermore, during the last 10 years, overwhelming evidence that the UPS (ubiquitin-proteasome system) plays a key role in the control of muscle mass has been provided. We review this evidence and discuss recent findings that may lead to the development of strategies to prevent or limit muscle wasting.
The ubiquitination/deubiquitination machinery is up-regulated in muscle wasting
The UPS involves two successive steps. The target protein is polyubiquitinated (i.e. tagged by the covalent attachment of a polyubiquitin degradation signal) and then it is recognized by the 26 S proteasome, which degrades the substrate into peptides (Figure 2) .
Polyubiquitination involves the sequential action of the ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) (Figure 2 ). Increased skeletal muscle mRNA levels for ubiquitin have been reported in several catabolic states in both rodents and humans [1, 2] . This adaptation prevails in both type-I and -II skeletal muscle fibres, but is more marked in the latter, as is the increased proteolysis. Elevated ubiquitin mRNA levels reflect increased transcription in muscles from acidotic and diabetic rats [4] . In vitro studies with glucocorticoid-treated L6 muscle cells demonstrated that Sp1 and MEK1 [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase-1) regulated ubiquitin transcription [4] .
E1 has low expression in skeletal muscle and its mRNA level is not regulated in catabolic states [1] . This is not surprising because E1 is an extremely active enzyme, capable of charging excess amounts of E2 with ubiquitin, and is a common element in all pathways of ubiquitination.
There are possibly up to 40 E2s in mammalian cells. However, only a rather small number of E2s are overexpressed in several, but not all, instances of muscle wasting. This includes the 14 kDa E2 [or HR6B/UBC2 (ubiquitinconjugating enzyme 2)], the 20 kDa E2, and UBC4/UBC5 isoforms [5] .
One E2 generally interacts with one or a limited number of E3 species (and conversely), which recognize specific protein substrates. E3s form by far the largest family of ubiquitination enzymes, with a possible 1000 members in humans. However, only a limited number of E3s that are up-regulated in muscle wasting have been identified. The first was E3␣/UBR1 (ubiquitin protein ligase E3 component n-recogin 1), the ubiquitous N-end rule RING (really interesting new gene)-finger ligase that functions with the 14 kDa E2. Both enzymes are involved in the ubiquitination of soluble muscle proteins. Although increased mRNA levels for the 14 kDa E2 and E3␣ have been observed in various catabolic models by Northern blotting, their respective protein levels did not change in such instances [1, 5] . Furthermore, and surprisingly, gene microarray experiments did not reveal any substantial increase in the expression of the two enzymes [6] . Finally, knockout mice for the 14 kDa E2 and E3␣ do not exhibit substantial changes in muscle size in the fasted and fed states respectively [5] . Thus the physiological significance of the N-end rule pathway in muscle protein ubiquitination remains totally unclear. Two musclespecific E3s, called atrogin-1/MAFbx (muscle atrophy F-box protein) and MuRF-1 (muscle-specific RING-finger 1) that seem to be systematically overexpressed in several catabolic conditions have been identified [7] . Atrogin-1/MAFbx and MuRF-1 interact with the ␣-actinin-2-calcineurin A complex in cardiomyocytes [8] and with titin, telethonin, myotilin, nebulin, troponin I, troponin T1, troponin T3 and myosin light-chain-2 in skeletal muscle cells [9] . There has been much interest in the elucidation of the mechanisms that regulate (3): polyubiquitination. The free ubiquitin (Ub) forms a thiol ester bond with the E1 (1), and then with an E2 (2); a given E2 and/or E3 covalently attaches a polyubiquitin degradation signal to the protein substrate (3).
Step (4): deubiquitination. Erroneously tagged protein substrates can be deubiquitinated by the DUBs.
Step (5): breakdown of the substrate. The polyubiquitin degradation signal is recognized by at least the non-ATPase S5a and the ATPase S6Ј subunits of the 19 S complex and detached from the substrate. The latter is unfolded, injected into the proteolytic chamber of the 20 S proteasome where it is cut into peptides, and the polyubiquitin degradation signal is recycled into free ubiquitin. The E2, E3 and DUB species that are activated in muscle wasting are shown in parentheses. the expression of these E3s because knockout mice for either enzyme were partially resistant to muscle atrophy. The increased transcription of atrogin-1/MAFbx is under the control of FoxO (forkhead box O), the forkhead transcription factor [10] , while MuRF-1 transcription is driven by the activation of NF-B (nuclear factor B) [11] . However, the latter paper challenged the role of atrogin-1/MAFbx in muscle wasting. Indeed, in these experiments where muscle wasting was clearly ubiquitin-dependent, the mRNA levels for atrogin-1/MAFbx were normal [11] .
Skeletal muscle also contains many isoforms of DUBs (deubiquitinating enzymes), which are very active in soluble muscle extracts. UBP45 (ubiquitinbinding protein 45) and UBP69 are two DUBs involved in the regulation of cell differentiation [5] . At least two other DUBs are overexpressed in muscle wasting. Gene array studies in four different muscle wasting conditions have identified USP14 (ubiquitin-specific protease 14), which associates with the proteasome [6] . Another recent paper has also identified USP19, a DUB that does not bind to the proteasome [12] . Although it is unknown whether the protein levels of either USP14 or USP19 are modified under such circumstances, it is likely that the up-regulation of such enzymes helps to recycle free ubiquitin more efficiently when the UPS is stimulated (Figure 2 ). However, the pattern of expression of USP19 is not strictly parallel to the enhanced ubiquitin-dependent proteolysis, but is inversely proportional to muscle mass. Indeed, preliminary data indicate that this enzyme may have very specific substrates and could play a role in cell growth [12] .
In vivo muscle ubiquitin-conjugates accumulate in some wasting conditions [1, 2, 5] , suggesting that their breakdown by the 26 S proteasome is ratelimiting. However, in other studies there was no accumulation of ubiquitinconjugates although the UPS was activated (see [13] for an example). Several explanations may account for such discrepancies. Intracellular levels of ubiquitin-conjugates depend on ubiquitination rates, on their rates of breakdown, and on DUB activities. Thus the apparent level of ubiquitin-conjugates may not change globally, although these distinct processes may be regulated. For example, an increased rate of ubiquitination could be totally masked by an enhanced breakdown of the conjugates. In vitro rates of ubiquitination of endogenous 125 I-labelled ubiquitin conjugates and of a model substrate of the N-end rule pathway (i.e. [ 125 I]␣-lactalbumin) increase in soluble muscle extracts from rats in various catabolic conditions [14, 15] . Conversely, rates of ubiquitination decreased in muscle extracts of thyroidhormone-deficient animals (where overall protein breakdown falls) and rose after treatment with these hormones [14] .
The 26 S proteasome is up-regulated in muscle wasting
Various mechanisms that regulate the proteolytic/peptidase activities of the proteasome (e.g. the synthesis, processing and post-translational modifications of proteasome subunits, the assembly of 20 S and 26 S proteasomes, the binding of proteasome activators and inhibitors etc.) are very poorly documented in skeletal muscle. Thus in the following section we concentrate on established observations in muscle wasting.
About 10 years ago, the increased proteolysis seen in atrophying incubated muscles from starved, denervated, tumour-bearing, acidotic, septic and insulinopaenic rats was found to be ATP-dependent. By contrast, the inhibition of calpains and/or cathepsins in such muscles does not eliminate the elevated rates of proteolysis [1, 2, 13] . ATP is required for the activation of ubiquitin by E1 and proteolysis by the 26 S proteasome. The demonstration that only proteasome inhibitors (lactacystin, MG132) also suppress the enhanced rates of overall proteolysis in wasting conditions [1] [2] [3] [4] 15] provided strong support for a major role of the proteasome in the breakdown of muscle proteins.
Proteasomes are tightly associated with myofibrils in mature skeletal muscle [16] and possess five peptidase activities as reported in other cell types (chymotrypsin-, trypsin-or caspase-like, and branched-chain amino acid-or small neutral amino acid-preferring activities [17] ). Compared to other tissues, both peptidase and proteolytic activities are low in rat muscle. Studies with artificial substrates have shown that the chymotrypsin-like peptidase activity increases in some muscle wasting conditions, but is unchanged in diabetes (reviewed in [1] ). Discrepancies between rates of overall muscle proteolysis and some specific proteasome activities may have several explanations. First, the 20 S proteasome population comprises at least six distinct subtypes in skeletal muscle, including constitutive proteasomes, immunoproteasomes, and their intermediate forms. Thus the properties of a 20 S proteasome population isolated from muscle represent the average properties of the whole set of proteasomes subtypes. Secondly, the hydrolysis of artificial substrates may not reflect the in vivo situation with endogenous substrates. However, and contrastingly, both chymotrypsin-and trypsin-like peptidase activities were reduced when skeletal muscle proteasome-dependent proteolysis was impaired by chemotherapy [1,18,18a] .
Expression and protein content of 20 S proteasome subunits
The 20 S proteolytic core associates with two 19 S regulatory complexes to form a 26 S proteasome (Figure 2 ). Numerous groups have reported that enhanced ATP-and/or proteasome-dependent rates of muscle proteolysis correlate with elevated mRNA levels for the ␤ catalytic and ␣ non-catalytic subunits of the 20 S proteasome [1] [2] [3] [4] . However, gene array experiments have shown that a small number of subunits are actually overexpressed in different muscle wasting conditions [6] . There is very limited information about the protein levels of 20 S proteasome subunits in catabolic states. Increased protein abundance of one 20 S proteasome subunit correlates with enhanced mRNA levels for other subunits in cancer cachexia (reviewed in [1] ). Conversely, when proteasome-dependent proteolysis was inhibited by chemotherapy to below basal levels, mRNA levels for 20 S proteasome subunits correlated with reduced protein levels of the two subunits [18,18a] . The overexpressed RC9 (rat C9) subunit entered active translation in the atrophying unweighted soleus muscle [1] , and an increase in transcribed RC3 proteasome subunit mRNA was observed in acidosis [4] . Glucocorticoids [1, 2, 4] and TNF-␣ (tumour necrosis factor ␣) [1, 3] up-regulate mRNA levels for 20 S proteasome subunits. Glucocorticoids induce proteasome C3 subunit transcription in L6 muscle cells by opposing the suppression of its transcription by NF-B, whereas the glucocorticoid-dependent increased transcription of ubiquitin involves Sp1 and MEK1 [4] . Thus the increased co-ordinated transcription of several genes in the UPS results from the activation of alternative signalling pathways.
Expression and protein content of subunits of the 19 S complex
Some, but not all, mRNA levels for ATPase and non-ATPase subunits of the 19 S complex are also up-regulated in muscle wasting. However, this upregulation clearly depends on a given catabolic state [1, 5, 15] . Furthermore, the mRNA levels and protein contents of the individual 19 S subunits are regulated independently, and do not systematically correlate with rates of proteolysis [3,18,18a] . The selective increased expression of some 20 S or 19 S proteasome subunits strongly suggests that these subunits may be rate-limiting in assembly of the mature complex [6] . Furthermore, these findings also suggest that, in muscle, in contrast to findings in yeast, different transcription factors or co-regulators appear to affect the expression of subgroups of proteasome subunits.
The major substrates of the muscle UPS are still poorly characterized
In several experiments, polyubiquitinated proteins accumulated preferentially in the myofibrillar, but not in the soluble, fraction of muscles from rodents in a catabolic state [1, 3, 19] . Furthermore, only ATP-depletion [1, 13] and proteasome inhibitors (but not inhibitors of the cathepsins or calpains) [1, 2] suppress the elevated 3-methylhistidine release by incubated atrophying muscles. Post-translational modifications of actin and pale myosins form 3-methylhistidine and its rate of appearance in incubation media only reflects the breakdown of these myofibrillar proteins [1] . These observations lead to the widely accepted concept that the major contractile proteins are substrates of the UPS. However, only a single myofibrillar protein has been identified so far as a ubiquitinated substrate of the proteasome. A yeast two-hybrid screen was performed to search for interaction partners of MuRF-1 in cultured myocytes that might be targets of its E3 activity. This screen identified troponin I as a MuRF-1 partner protein in these cells [20] . Other myofibrillar proteins (i.e. nebulin, troponins T1 and T3, myosin-light-chain-2 etc.) that also interact with MuRF-1 have been recently identified in skeletal muscle cells [9] . By contrast, other yeast two-hybrid screen experiments identified either ␣-actinin-2-calcineurin A complex [8] or MyoD [21] as binding partners of atrogin-1/MAFbx E3. Thus the proteins that are ubiquitinated in the myofibrillar fraction are still unidentified, except cardiac troponin I. Furthermore, substantial additional experiments are clearly required to demonstrate that the major contractile proteins (actin and pale myosin heavy chains) are actually ubiquitinated. Alternatively, the 26 S proteasome also degrades non-ubiquitinated protein substrates. In skeletal muscle at least, troponin C is degraded by the 26 S proteasome via a ubiquitin-independent mechanism [1] . Oxidized proteins are also believed to be degraded by the 20 S proteasome in a ubiquitin-independent fashion [1] . 
Functional relationships with other proteolytic enzymes
The 26 S proteasome degrades proteins only into peptides. Except when presented on MHC class I molecules, these peptides must undergo further hydrolysis, releasing free amino acids [1] . The extralysosomal peptidase TPP II (tripeptidyl-peptidase II) degrades peptides generated by the proteasome into tripeptides, which are further hydrolysed into free amino acids by aminopeptidases (Figure 3) . TPP II expression, protein content and activity increases in septic muscles. In addition, the glucocorticoid receptor antagonist RU 38486 blunts these adaptations, indicating that glucocorticoids participate in the up-regulation of TPP II (reviewed in [1] ).
Conversely, other proteases may act upstream of the proteasome ( Figure  3 ). Specific interactions between the myofibrillar proteins appear to protect them from ubiquitin-dependent degradation, and the rate-limiting step in their degradation is probably their dissociation from the myofibril [1] . Calpains play key roles in the disassembly of sarcomeric proteins and in Z-band disintegration, resulting in the release of myofilaments. These data suggest that calpains are acting upstream of the proteasome [1] . Caspase 3 has also been implicated in the initial breakdown of actin [22] . Finally, cathepsin L is differentially up-regulated in various wasting conditions, and cathepsin L mRNA levels closely follow adaptations in the UPS [23] . These observations have been confirmed by gene-array experiments [5] . It remains to be demonstrated clearly whether there are functional connections between calpains, caspase 3, cathepsin L and the UPS. However, the expression of several proteolytic genes (including those encoding cathepsin L and several key components of the UPS) was down-regulated in mice knocked out for the muscle-specific calpain p94 (reviewed in [1] ).
Signalling pathways responsible for muscle wasting
Major advances have been made in the elucidation of signalling pathways that regulate the UPS in muscle (see [24] for a recent detailed review). In brief, various cytokines (i.e. TNF-␣, interleukin-6 etc.), hormones (i.e. glucocorticoids) and myostatin up-regulate the UPS [1] [2] [3] [4] 13, 24] . Conversely, insulin or IGF-1 (insulin-like growth factor-1) inhibit the UPS [1, 2, 4, 10] . The current concept is that the NF-B transcription factor family mediates the activation of the UPS in most, if not all, muscle catabolic states via upstream signalling molecules that include cytokines and/or reactive oxygen species [11, 24] (Figure 4) .
Possible strategies to prevent muscle wasting
Muscle wasting is a key metabolic adaptation that presents many advantages in the short-term (see above). However, sustained muscle wasting rapidly becomes deleterious because the ability of the organism to recover from stress and/or pathologies is rapidly impaired; it results in prolonged hospitalization.
Furthermore, pronounced muscle wasting ultimately results in increased morbidity and mortality when key muscles (i.e. respiratory muscles) become atrophied ( Figure 1 ). For example, a large number of cachectic cancer, septic, burned, or traumatized patients die when muscle protein loss exceeds 70% (which corresponds to a loss of body weight of about 30%). Thus preventing muscle wasting is of major clinical importance and is a critical issue in terms of is also repressed (either because insulin and/or IGF-1 circulating levels are low or because insulin and/or IGF-1 resistance prevails). Thus, both Akt/PKB (protein kinase B) and the FoxO transcription factor are poorly phosphorylated (P). All these events lead to increased transcription of atrogins (i.e. atrophy genes), which ultimately results in a stimulation of the UPS and in muscle atrophy. By contrast, in anabolic situations (black lines) insulin and/or IGF-1 activate PI3K. In that case, both Akt and FoxO are highly phosphorylated, and the latter event is ultimately responsible for repressed transcription of atrogins. In addition, the high levels of phosphorylated Akt induce increased protein synthesis (not shown). All these adaptations result in muscle growth. health care costs (Figure 1) . Recent studies have shown that there are at least three possible strategies to prevent the stimulation of the UPS in muscle wasting diseases ( Figure 5 ). The first involves inhibitors of upstream modifiers like glucocorticoid, cytokine, and/or free radical production. A second possibility is to target the NF-B pathway that is induced by one or several of the upstream modifiers. Finally, one may target some components of the ubiquitination (or perhaps deubiquitination) machinery or the proteasome itself. Any approach has advantages but also drawbacks and limitations (reviewed in [25] ). 
Conclusion
How the UPS degrades muscle proteins, and more particularly contractile proteins, remains largely unknown. Crucially, we need to identify the precise substrates of the UPS in muscle wasting and the precise signal(s) that target(s) myofibrillar proteins for breakdown. The complexity of the UPS itself and of its signalling pathways will clearly impede the identification of such mechanisms. Microarray analyses of transcription profiles [5] and (so far lacking) proteomic surveys of atrophying muscles should provide extremely valuable information and reveal new players in the muscle UPS. For example, the only two E3s that are believed to play a major role in muscle wasting have been initially characterized in three different models of inactivity (denervation atrophy, unweighting and immobilization [7] ). Although the expression of these enzymes is also enhanced in other catabolic conditions [6] , it is likely that other muscle-critical E3s remain to be identified in other catabolic conditions. Elucidating proteolytic mechanisms both upstream and downstream of the UPS that result in the complete degradation of muscle proteins is also of major importance. In theory the inhibition of any proteolytic enzyme involved in the sequential breakdown of the contractile proteins should prevent or at least limit muscle wasting. Studies in the laboratory of the authors that led to some concepts reported herein are supported by the Institut National de la Recherche Agronomique, the Institut National de la Santé et de la Recherche Médicale, the Ministère Français de la Recherche, and Nestlé.
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